Administration of infliximab in Crohn's disease does not deplete complement components C3 and C4.

Arnott, I D

Administration of infliximab in Crohn's disease does not deplete complement components C3 and C4. [electronic resource] - The American journal of gastroenterology Nov 2000 - 3326-7 p. digital

Publication Type: Letter

0002-9270

10.1111/j.1572-0241.2000.03325.x doi


Adult
Antibodies, Monoclonal--therapeutic use
Complement C3
Complement C4
Crohn Disease--drug therapy
Female
Gastrointestinal Agents--therapeutic use
Humans
Infliximab
Male
Prospective Studies